Cardinal Health (CAH)
(Delayed Data from NYSE)
$113.17 USD
+0.78 (0.69%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $113.24 +0.07 (0.06%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.17 USD
+0.78 (0.69%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $113.24 +0.07 (0.06%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
Is Cardinal Health (CAH) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Medical Stocks Lagging Cardinal Health (CAH) This Year?
by Zacks Equity Research
Here is how Cardinal Health (CAH) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
Reasons to Add Cardinal Health (CAH) to Your Portfolio Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from a solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cardinal (CAH) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Cardinal (CAH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What's in Store for Cooper Companies (COO) in Q4 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fiscal fourth-quarter results are likely to reflect segmental strength.
McKesson (MCK) Announces Availability of FDA-Cleared Drug
by Zacks Equity Research
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for breast cancer.
Zacks.com featured highlights Cboe Global Markets, Cardinal Health, Assurant, Installed Building Products and FedEx
by Zacks Equity Research
Cboe Global Markets, Cardinal Health, Assurant, Installed Building Products and FedEx have been highlighted in this Screen of The Week article.
Nevro's (NVRO) Latest Buyout to Boost SI Joint Pain Treatment
by Zacks Equity Research
Nevro's (NVRO) latest acquisition is likely to bring long-term pain relief to people suffering from chronic low back pain associated with the SI joint.
5 Dividend Stocks Having Strong Growth Potential
by Sweta Killa
Cboe Global (CBOE), Cardinal Health (CAH), Assurant (AIZ), Installed Building Products (IBP) and FedEx (FDX) have a strong dividend growth potential.
5 Broker-Friendly Stocks to Keep an Eye on Amid Volatility
by Maharathi Basu
We believe that stocks like Brinker International (EAT), Cardinal Health (CAH), The Andersons (ANDE), Avnet (AVT) and Group 1 Automotive (GPI) should be on an investor's watchlist.
This Combination of 3 Stocks Provides Monthly Income
by Derek Lewis
Investors who select stocks in a structured manner can create a portfolio that pays them monthly. Who doesn't love payday?
3 Reasons to Retain Inspire Medical (INSP) Stock for Now
by Zacks Equity Research
Inspire Medical's (INSP) focus on R&D raises optimism about the stock.
Inari Medical's (NARI) PEERLESS II RCT to Boost Patient Outcome
by Zacks Equity Research
Inari Medical's (NARI) latest announcement of first patient enrollment in PEERLESS II RCT is likely to aid in changing guidelines in treating intermediate-risk PE patients globally.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Cencora (COR) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.
3 Reasons to Retain Ecolab (ECL) Stock in Your Portfolio
by Zacks Equity Research
Ecolab's (ECL) strength in business raises optimism about the stock.
Cardinal Health, Inc. (CAH) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
3 Reasons Why Growth Investors Shouldn't Overlook Cardinal (CAH)
by Zacks Equity Research
Cardinal (CAH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Cardinal Health (CAH) Gets FDA Warning for Monoject Syringes
by Zacks Equity Research
The FDA is alerting healthcare providers and facilities against the use of Cardinal Health's (CAH) Monoject syringes with syringe pumps and PCS pumps.
Should Value Investors Buy Cardinal Health (CAH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Medical Stocks Lagging Arch Therapeutics (ARTH) This Year?
by Zacks Equity Research
Here is how Arch Therapeutics, Inc. (ARTH) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.
Why You Should Add DaVita (DVA) Stock to Your Portfolio
by Zacks Equity Research
DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.